Phoenix, AZ
How can you ensure precision, reproducibility and translational relevance when conducting toxicology testing? With more predictive iPSC-based platforms.
Ncardia will be at the American College of Toxicology (ACT) 2025 Annual Meeting, ready to discuss our scalable, high-throughput iPSC solutions and how they meet the complex demands of cardiac, neurological and stem cell safety testing.
Schedule a meeting with us to see how we can help you accelerate timelines, reduce reliance on animal models and generate more predictive safety data from early screening through regulatory submission.
For more than a decade, Ncardia has been pioneering innovations in human induced pluripotent stem cells (iPSC). Our iPSC drug discovery platforms have been successfully leveraged by large biopharmas, up-and-coming drug discovery firms and multinational research consortia to advance therapeutic candidates for cardiovascular, neurological and other disease areas.